Gas tamponade is more effective for RRD

Article

Using a gas tamponade, compared to an air tamponade, is more effective when treating rhegmatogenous retinal detachment (RRD).

Using a gas tamponade, compared to an air tamponade, is more effective when treating rhegmatogenous retinal detachment (RRD).

A team led by Dr H Stevie Tan, Academic Medical Center, University of Amsterdam, The Netherlands, examined the records of 524 cases of 523 patients that experienced primary vitrectomy for RRD with air or sulphur hexafluoride with a follow-up of at least three months. Cases with inferior retinal breaks were excluded from the study.

Of the patients included in the studied, 318 were treated with gas and 128 were treated with air. Eyes treated with air and gas had 81% and 86.9% chance of primary success, respectively.

A confounding factor was the involvement of lower retinal quadrants in the retinal detachment (RD). After this confounder was corrected the comparison between air and gas tamponade was statistically significant with regards to success rate.

Overall, gas tamponades are superior to air tamponades in RD cases with involvement of the lower quadrants. Air tamponades should only be used in RDs that are restricted to the superior quadrants.

The abstract can be found in the British Journal of Ophthalmology.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.